Results 11 to 20 of about 12,752 (178)

Cutaneous reactions during treatment with Nifurtimox or Benznidazole among Trypanosoma cruzi seropositive adults without symptomatic cardiomyopathy: A safety sub analysis of a placebo-controlled randomised trial. [PDF]

Trop Med Int Health
Abstract Objectives To determine, in a randomised placebo‐controlled trial, if cutaneous adverse reactions during treatment (CARDT) with Benznidazole occur as often as with Nifurtimox, and whether the dose and duration of treatment change that frequency.
Villar JC, Saavedra MF, Bermúdez PA, Herrera EV, Vásquez SM, Arango H, Camacho A, Olivera MJ.   +7 more
europepmc   +2 more sources

Use of benznidazole to treat chronic Chagas disease: An updated systematic review with a meta-analysis.

PLoS Neglected Tropical Diseases, 2022
BackgroundApproximately 6 million people worldwide are affected by Chagas disease, with many in the chronic phase of the disease (CCD). It is crucial to evaluate the effectiveness of benznidazole for CCD treatment.Methods/principal findingsWe updated a ...
Clara Crespillo-Andújar, Belén Comeche, Davidson H Hamer, Ingrid Arevalo-Rodriguez, Noelia Alvarez-Díaz, Javier Zamora, José A Pérez-Molina   +6 more
doaj   +1 more source

Synthesis, In Silico Studies, Antiprotozoal and Cytotoxic Activities of Quinoline‐Biphenyl Hybrids [PDF]

, 2020
This is the pre-peer reviewed version of the following article: Synthesis, In Silico Studies, Antiprotozoal and Cytotoxic Activities of Quinoline‐Biphenyl Hybrids, which has been published in final form at https://doi.org/10.1002/slct.201903835.
Carda, Miguel, Cardona G, Wilson I, Coa, Juan Carlos, Conesa Milián, Laura, Robledo, Sara M., Upegui Zapata, Yulieth Alexandra, Yepes, Andrés   +6 more
core   +1 more source

Access to Chagas disease treatment in the United States after the regulatory approval of benznidazole.

PLoS Neglected Tropical Diseases, 2020
Approximately 300,000 persons in the United States (US) are infected with Trypanosoma cruzi, the protozoan that causes Chagas disease, but less than 1% are estimated to have received antiparasitic treatment.
Kota Yoshioka, Jennifer Manne-Goehler, James H Maguire, Michael R Reich   +3 more
doaj   +1 more source

IL-10/STAT3/SOCS3 Axis Is Involved in the Anti-inflammatory Effect of Benznidazole

Frontiers in Immunology, 2019
Anti-parasitic treatment for Chagas disease mainly relies on benznidazole, which is virtually the only drug available in the market. Besides its anti-parasitic effects, benznidazole has anti-inflammatory properties. In this work we studied the mechanisms
Ágata C. Cevey, Federico N. Penas, Catalina D. Alba Soto, Gerardo A. Mirkin, Nora B. Goren   +4 more
doaj   +1 more source

Miltefosine and Benznidazole Combination Improve Anti-Trypanosoma cruzi In Vitro and In Vivo Efficacy

Frontiers in Cellular and Infection Microbiology, 2022
Drug repurposing and combination therapy have been proposed as cost-effective strategies to improve Chagas disease treatment. Miltefosine (MLT), a synthetic alkylphospholipid initially developed for breast cancer and repositioned for leishmaniasis, is a ...
Julián Ernesto Nicolás Gulin, Julián Ernesto Nicolás Gulin, Margarita María Catalina Bisio, Margarita María Catalina Bisio, Daniela Rocco, Jaime Altcheh, María Elisa Solana, María Elisa Solana, Facundo García-Bournissen, Facundo García-Bournissen   +9 more
doaj   +1 more source

Treatment With Suboptimal Dose of Benznidazole Mitigates Immune Response Molecular Pathways in Mice With Chronic Chagas Cardiomyopathy

Frontiers in Cellular and Infection Microbiology, 2021
Chronic Chagas cardiomyopathy (CCC) is the most frequent and severe form of Chagas disease, a neglected tropical illness caused by the protozoan Trypanosoma cruzi, and the main cause of morbimortality from cardiovascular problems in endemic areas ...
Priscila Silva Grijó Farani, Priscila Silva Grijó Farani, Khodeza Begum, Glaucia Vilar-Pereira, Isabela Resende Pereira, Igor C. Almeida, Sourav Roy, Joseli Lannes-Vieira, Otacilio Cruz Moreira   +8 more
doaj   +1 more source

Trypanocidal Effects of Polyprenylated Benzophenone Enriched Brazilian Red Propolis Extract and Its Isolated Constituent. [PDF]

Chem Biodivers
In vitro trypanocidal activity of a polyprenylated benzophenone‐enriched Brazilian red propolis extract (SEBz) and its major constituents, guttiferone E/xanthochymol (GUT/XAN) and oblongifolin B (OBL), exhibit in vitro trypanocidal activity against Trypanosoma cruzi, inducing ultrastructural damage with moderate cytotoxicity and no significant ...
Oliveira ND, Pagotti MC, Paula LAL, Paixão MZ, Albino Dos Santos D, de Freitas RF, Ambrósio SR, Veneziani RCS, Bastos JK, Magalhães LG.   +9 more
europepmc   +2 more sources

High-dose benznidazole in a 62-year-old Bolivian kidney transplant recipient with Chagas central nervous system involvement

International Journal of Infectious Diseases, 2019
There is little published data on benznidazole dosing, or levels in cerebrospinal fluid. In this report, we describe the clinical course of an immunosuppressed patient with Chagas central nervous system involvement.
M. Montero, M. Mir, E. Sulleiro, J.L. Avalos Esquivel, E. García López, D. Molina-Morant, I. López Montesinos, L. Sorlí, G. Veliz Espinosa, E. Mounteis Oliva, M. Crespo, I. Monge, J.P. Horcajada, S. Grau, J. Pascual   +14 more
doaj   +1 more source

Unveiling challenges in real-time PCR strategies for detecting treatment failure: observations from clinical trials on chronic Chagas disease

Frontiers in Parasitology, 2023
Chagas disease (CD) caused by Trypanosoma cruzi remains a Neglected Tropical Disease with limited access to diagnosis and treatment, particularly for chronically infected patients.
Alejandro G. Schijman
doaj   +1 more source